ImmunoVaccine Inc. (TSE:IMV) Director Alfred Smithers purchased 10,000 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was purchased at an average price of C$2.00 per share, for a total transaction of C$20,000.00.
Alfred Smithers also recently made the following trade(s):
- On Friday, February 2nd, Alfred Smithers purchased 10,000 shares of ImmunoVaccine stock. The stock was purchased at an average price of C$2.05 per share, for a total transaction of C$20,500.00.
- On Wednesday, January 24th, Alfred Smithers purchased 33,600 shares of ImmunoVaccine stock. The stock was purchased at an average price of C$2.09 per share, for a total transaction of C$70,224.00.
ImmunoVaccine Inc. (TSE IMV) traded down C$0.07 during mid-day trading on Thursday, reaching C$1.93. The company had a trading volume of 8,525 shares, compared to its average volume of 144,702. ImmunoVaccine Inc. has a 12-month low of C$0.97 and a 12-month high of C$2.55. The stock has a market cap of $259.34, a price-to-earnings ratio of -22.22 and a beta of 0.47.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.com-unik.info/2018/02/08/alfred-smithers-purchases-10000-shares-of-immunovaccine-inc-imv-stock.html.
Immunovaccine Inc, a clinical stage biopharmaceutical company, develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.
Receive News & Ratings for ImmunoVaccine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoVaccine and related companies with MarketBeat.com's FREE daily email newsletter.